Brief: Shandong Boan Biotechnology Announces Licensing Of Dulaglutide Injection In US
11/06/2026 15:03
BRIEF-Shandong Boan Biotechnology Announces Licensing Of Dulaglutide Injection In US June 11 (Reuters) - Shandong Boan Biotechnology Co Ltd 6955.HK:
LICENSING OF DULAGLUTIDE INJECTION IN U.S.
ENTERS LICENSING AGREEMENT FOR BA5101 IN U.S.
Further company coverage: 6955.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shandong Boan Biotechnology
See all newsBrief: Shandong Boan Biotechnology Says CDE Clears IND Application For BA1203
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil